IGF‐1 and IGFBP‐3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

IGF‐1 and IGFBP‐3 may influence risk of prostate cancer through their roles in cellular growth, metabolism and apoptosis, however, epidemiologic results have been inconsistent. The role of obesity in prostate cancer risk is not clearly understood, but hyperinsulinemia‐related increases in bioactive IGF‐1 levels, associated with obesity, could be a component of the relationship between the IGF‐axis and prostate cancer. We conducted a nested case–control study in the prospective Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial to examine associations between IGF‐1 and IGFBP‐3 and risk of prostate cancer. A total of 727 incident prostate cancer cases and 887 matched controls were selected for this analysis. There was no clear overall association between IGF‐1, IGFBP‐3 and IGF‐1:IGFBP‐3 molar ratio (IGFmr) and prostate cancer risk, however, IGFmr was associated with risk in obese men (BMI > 30, p‐trend = 0.04), with a greater than 2‐fold increased risk in the highest IGFmr quartile (OR 2.34, 95% CI 1.10–5.01). Risk was specifically increased for aggressive disease in obese men (OR 2.80, 95% CI 1.11–7.08). In summary, our large prospective study showed no overall association between the insulin‐like growth factor axis and prostate cancer risk, however, IGFmr was related to risk for aggressive prostate cancer in obese men. © 2007 Wiley‐Liss, Inc.

[1]  D. Albanes,et al.  Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality , 2007, Cancer.

[2]  Carmen Rodriguez,et al.  Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort , 2007, Cancer Epidemiology Biomarkers & Prevention.

[3]  D. Freedman,et al.  Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004 , 2007, Cancer Epidemiology Biomarkers & Prevention.

[4]  Dallas R. English,et al.  Body size and composition and prostate cancer risk: systematic review and meta-regression analysis , 2006, Cancer Causes & Control.

[5]  B. Lokeshwar,et al.  Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? , 2006, Urologic oncology.

[6]  N. Wald,et al.  Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies , 2006, British Journal of Cancer.

[7]  D. English,et al.  Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[8]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[9]  J. Droz,et al.  Insulin-Like Growth Factor (IGF) family and prostate cancer. , 2006, Critical reviews in oncology/hematology.

[10]  S. Taneja,et al.  Obesity and prostate cancer. , 2006, The Canadian journal of urology.

[11]  R. Kineman,et al.  Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. , 2006, Endocrinology.

[12]  Ruth Etzioni,et al.  Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase , 2006, Cancer.

[13]  Robert N Hoover,et al.  Methods for etiologic and early marker investigations in the PLCO trial. , 2005, Mutation research.

[14]  G. Cancel-Tassin,et al.  Genetic susceptibility to prostate cancer , 2005, Medecine sciences : M/S.

[15]  E. Giovannucci,et al.  Role of diet in prostate cancer development and progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Walsh.  The association of body mass index and prostate-specific antigen in a population-based study. , 2005, The Journal of urology.

[17]  J. Potter,et al.  Variation in Plasma Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3: Personal and Lifestyle Factors (United States) , 2005, Cancer Causes & Control.

[18]  P. Galan,et al.  A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial , 2005, Cancer Epidemiology Biomarkers & Prevention.

[19]  A. Wolk.  Diet, lifestyle and risk of prostate cancer , 2005, Acta oncologica.

[20]  E. Crawford,et al.  Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. , 2005, Urology.

[21]  W. Willett,et al.  Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era , 2005, Cancer Causes & Control.

[22]  J. Gohagan,et al.  Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. , 2005, Journal of the National Cancer Institute.

[23]  A. Papatsoris,et al.  Novel insights into the implication of the IGF-1 network in prostate cancer. , 2005, Trends in molecular medicine.

[24]  E. Riboli,et al.  Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[26]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[27]  P. Stattin,et al.  High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[29]  D. Albanes,et al.  Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  T. Peters,et al.  Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control study , 2004, International journal of cancer.

[31]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[32]  J. Witte,et al.  Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States) , 2003, Cancer Causes & Control.

[33]  D. Albanes,et al.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.

[34]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[35]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[36]  L. Bégin,et al.  Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. , 2002, The Journal of urology.

[37]  K. Helzlsouer,et al.  Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  T. Fears,et al.  Insulin-like growth factors and prostate cancer: a population-based case-control study in China. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  E. Riboli,et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.

[40]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[41]  E. Metter,et al.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[42]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[43]  T. Tammela,et al.  Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. , 2000, The Journal of clinical endocrinology and metabolism.

[44]  J. Khosravi,et al.  Immunoassay of insulin-like growth factor-binding protein-3 (IGFBP-3): new means to quantifying IGFBP-3 proteolysis. , 2000, The Journal of clinical endocrinology and metabolism.

[45]  P. Cohen,et al.  Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. , 1999, The Journal of endocrinology.

[46]  B. Foster,et al.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. , 1999, Cancer research.

[47]  C. Mantzoros,et al.  Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[49]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[50]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[51]  J. Argente,et al.  Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: effect of short- and long-term weight reduction. , 1997, The Journal of clinical endocrinology and metabolism.

[52]  Y. Song,et al.  Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone , 1997, International Journal of Obesity.

[53]  J. Kaprio,et al.  Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. , 1996, The Journal of clinical investigation.

[54]  M. Binoux,et al.  Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases. , 1996, Growth regulation.

[55]  N. Pedersen,et al.  Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. , 1996, The Journal of clinical endocrinology and metabolism.

[56]  H. Orskov,et al.  Free insulin-like growth factors in human obesity. , 1995, Metabolism: clinical and experimental.

[57]  J. Ketelslegers,et al.  Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.

[58]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[59]  K. Noonan,et al.  DECREASED SEX HORMONE BINDING GLOBULIN (SHBG) AND INSULIN‐LIKE GROWTH FACTOR BINDING PROTEIN (IGFBP‐1) IN EXTREME OBESITY , 1990, Clinical endocrinology.

[60]  D. Snowdon,et al.  Diet, obesity, and risk of fatal prostate cancer. , 1984, American journal of epidemiology.

[61]  B. Posner,et al.  Insulin-like growth factors: a role in growth hormone negative feedback and body weight regulation via brain. , 1983, Science.

[62]  Noel S Weiss,et al.  Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulin , 2005, Cancer.

[63]  J. Ku,et al.  Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. , 2003, Urology.

[64]  J. Bub,et al.  Prostate Cancer Cell-Adipocyte Interaction LEPTIN MEDIATES ANDROGEN-INDEPENDENT PROSTATE CANCER CELL PROLIFERATION THROUGH c-Jun NH 2 -TERMINAL KINASE* , 2003 .

[65]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[66]  M. Thorén,et al.  Determinants of circulating insulin-like growth factor-I. , 1999, Journal of endocrinological investigation.

[67]  A. Boccuzzi,et al.  Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features , 1999, Journal of endocrinological investigation.

[68]  C. Mantzoros,et al.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. , 1997, British Journal of Cancer.

[69]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.

[70]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.